Design, Synthesis, and Structure–Activity Relationship Study of μ-Conotoxin KIIIA toward Na V 1.4

Authors:

Abstract
NaV1.4 expressed in skeletal muscle, is a validated target for treating neuromuscular disorders. While the μ-conotoxin KIIIA is the one of the smallest conopeptide inhibitors of NaV1.4, its therapeutic potential is limited by potency and synthetic complexity. Using a computational model, we designed analogues with added positive charges, yielding [K7R, A15R]KIIIA-1 (IC50 = 20.5 nM). Further optimization produced [S5R]KA with high potency (IC50 = 5.1 nM) but poor enzymatic stability (t1/2 < 4 h). To improve stability, we replaced Cys4 with penicillamine (Pen), generating C4Pen. This analogue maintained excellent activity (IC50 = 11.1 nM) and significantly improved stability (t1/2 > 8 h), and both analogues preferentially inhibited NaV1.4 with moderate activity at NaV1.2 and NaV1.7 and exhibited no detectable inhibition of NaV1.5. In vivo studies confirmed that both [S5R]KA and C4Pen induce potent muscle relaxation. This structure-based optimization combines electrostatic mutagenesis with Pen-mediated stabilization, yielding a promising peptide therapeutic candidate.
Funding Information
  • National Health and Medical Research Council (APP2014544)
  • Qingdao National Laboratory for Marine Science and Technology (2022QNLM030003)
  • Major Scientific and Technological Innovation Project of Shandong Province (2022CXGC020414)
  • Fundamental Research Funds for the Central Universities (202441004)
  • National Natural Science Foundation of China (22201164)
  • National Natural Science Foundation of China (32171267)
  • National Natural Science Foundation of China (82122064)
  • Jinan Innovation Team Project (202333022)
  • Qingdao Marine Biomedical Research Institute, Ocean University of China (YZ1-25-04)

This publication has 52 references indexed in Scilit: